EQS-News

After a mixed 2023 financial year, aap makes a strong start to the 2024 financial year

EQS-News: aap Implantate AG / Key word(s): Interim Report/Corporate Action After a mixed 2023 financial year, aap makes a strong start to the 2024 financial year 15.02.2024 / 13:04 CET/CEST The issuer is solely responsible for the content of this announcement. Silver: significant acceleration in patient recruitment with over 130 patients as of the end of January 2024. Sales: very good start to the 2024 financial year Start of MDR certification In the past financial year, aap Implantate AG ("aap" or "Company") was able to significantly accelerate patient recruitment with the realignment of the world's first clinical human study for its innovative antibacterial implant technology. At the same time, the number of predefined, product-related incidents has so far been significantly lower than assumed values, which, if the results remain the same, would enable early completion of patient recruitment in mid-2024 and thus the completion of the study after the end of the follow-up period in mid-2025. Building on these promising developments, aap will continue its efforts to attract significant third-party funding for the industrial expansion of the technology in the 2024 financial year. After a mixed 2023 financial year in the LOQTEQ trauma division, aap was able to make a positive start to the new 2024 financial year. In January, sales in Germany increased significantly by 30% compared to sales in January 2023. International business was up 10% year-on-year and the U.S. stayed within budget for Q1 with the aim of increasing profitability and consolidating sales. With the conclusion of a distribution agreement with a leading global medical technology company and supplier of products in the field of spine treatment and orthopedics for the French market with the highest-selling system LOQTEQ VA-Radius system, a further step in the sustainable sales development could be made. Due to the difficult forecast for annual sales, aap is cautiously optimistic about sales in 2024 of between EUR 11.5 million and EUR 13.0 million.